explore -WSS

explore

author：explore 2025-09-29 11:24:31 - browse：947

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Key Senate committee drafts bipartisan bill to stem drug shortages

WSS

Cue Health's Covid

H5N1 bird flu virus started spreading in cows in Texas in December

What we know about the American soldier detained in North Korea

Why rehabilitation engineers need to center patients in their research

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Flagship, Pfizer team up in deal worth up to $7 billion

entertainment

explore

leisure time

Guidelines to prevent youth baseball injuries need more muscle

A look at other Americans who have crossed into North Korea over the years

Supreme Court strikes down use of affirmative action

Johnson & Johnson sues to stop Medicare negotiation

Malaria cases in Florida and Texas: Here’s what you need to know

UnitedHealth financials solid despite Change Healthcare cyberattack

Continuity nursing helped my family in our darkest PICU moments

Dogs on Prozac: What pet anti

Medical records are filled with copy

After traumatic brain injury, life support decisions can use more time

entertainment

Q&A: Jennifer Adair on making gene therapy available globally

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Twill hunts for pharma partner to market its depression app

Lack of darker skin in textbooks, journals harms patients of color

BridgeBio heart drug succeeds in pivotal study

FDA seeking to stop procedures at two unregulated stem cell clinics

hotspot

hotspot

focus

knowledge